COP vs LLY: Which Is the Better Buy?
Side-by-side comparison of ConocoPhillips and Eli Lilly and Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-17.
ConocoPhillips · Energy
$108.44
-21.6% upside to fair value
Grade D
VS
Eli Lilly and Company · Healthcare
$1,179.09
+31.7% upside to fair value
High Conviction
Grade A
High Quality
QuantHub Verdict
LLY has more upside to fair value
(+31.7%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
COP |
LLY |
| Current Price |
$108.44 |
$1,179.09 |
| Fair Value Estimate |
$85.04 |
$1,552.32 |
| Upside to Fair Value |
-21.6%
|
+31.7%
|
| Market Cap |
$132.1B |
$1,110.4B |
| Forward P/E |
18.4x
|
—
|
| EV / EBITDA |
6.1x
|
34.3x
|
| Price / Sales |
2.3x
|
14.6x
|
| Price / FCF |
8.6x
|
77.7x
|
| Revenue Growth YoY |
-2.5%
|
+55.5%
|
| Gross Margin |
29.2%
|
83.5%
|
| Operating Margin |
18.3%
|
45.9%
|
| Return on Equity |
11.3%
|
101.3%
|
| Dividend Yield |
0% |
0.55% |
| FCF Yield |
11.64%
|
1.29%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
ConocoPhillips is a major player in the Energy sector focused on Oil & Gas Exploration & Production. The company demonstrates medium business quality with a stable competitive position but faces earnings pressure as reflected in a 23.4% decline in earnings and a 2.5% decline in revenue in the most recent quarter year-over-year. Despite a solid ROE of 11.3% and attractive margins (gross margin 29.…
Eli Lilly is a global biopharma company whose exceptionally profitable cardiometabolic franchises, led by Mounjaro and Zepbound, are driving a high-quality growth phase: revenue rose 55.5% year over year and earnings rose 168.0% year over year in the most recent quarter, while gross, operating, and net margins were 83.5%, 45.9%, and 35.0%, respectively. Business quality is high because tirzepatid…
Accumulation Zones
| Metric |
COP |
LLY |
| Zone Low |
$63.78 |
$1,164.24 |
| Zone High |
$72.28 |
$1,319.47 |
| In Buy Zone? |
No
|
Yes
|